Cryobiopsy was initially utilized for tumor debulking of endobronchial lesions. Since then, its use has expanded to aid in the diagnosis of interstitial lung disease (ILD) and in surveillance of lung transplant recipients. It is now gaining popularity in the evaluation and diagnosis of peripheral lung lesions. Prior to the development of the 1.1 mm cryoprobe, en bloc removal was required immediately after biopsy was performed, which increased procedural risk. Currently, guidelines and protocols for its use in peripheral lung lesions are not standardized but instead have been extrapolated from its use in the ILD population. Cryobiopsy allows larger samples to be obtained with less crush artifact, providing more tissue for diagnostic analysis and molecular testing. Severe bleeding and pneumothorax are the risks most associated with cryobiopsy, which may be outweighed by the ability to obtain a higher-quality sample with a high diagnostic yield as compared to other existing modalities.